IntelGenx, RedHill Biopharma announce European marketing application for RIZAPORT.

IntelGenx and RedHill Biopharma have announced that their European Marketing Authorization Application for RIZAPORT, an oral thin film formulation of rizatriptan for acute migraines, has been validated and is under review by the German Federal Institute for Drugs and Medical Devices. The companies are also working with the FDA to address remaining Chemistry, Manufacturing and Controls issues and secure a compliant raw material source for potential U.S. approval. RIZAPORT offers an attractive therapeutic alternative for many migraine patients.